Literature DB >> 10822092

Inhibition of calcineurin activity and protection against cyclosporine A induced cytotoxicity by prednisolone sodium succinate in human peripheral mononuclear cells.

S Sipka1, K Szücs, S Szántó, I Kovács, G Lakos, P Antal-Szalmás, G Szegedi, P Gergely.   

Abstract

We have investigated the effects of prednisolone sodium succinate (Pss) and cyclosporin A (CSA), applied alone or concurrently, on the release of arachidonic acid (AA) (cytosolic phospholipase A(2) (cPLA(2)) activity) and on the calcineurin (CN) activity of human peripheral blood mononuclear cells (PBMC). The cytotoxic damage to the cells treated by the drugs was estimated by the release of lactate dehydrogenase (LDH). We found that Pss (10(-5) M) could inhibit the CN activity and higher concentrations (10(-4) M) could decrease the cytotoxic damage caused by CSA (10(-4) M) during their combined application. CSA had no specific effect on the release of AA from the cells. In the combined clinical use of glucocorticosteroids (GCS) and CSA, their additive inhibitory effect on CN activity and the protective membrane influence of GCS against the cytotoxicity of CSA may be beneficial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822092     DOI: 10.1016/s0162-3109(00)00180-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  2 in total

1.  Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.

Authors:  S Sipka; K Szucs; S Szántó; I Kovács; G Lakos; E Kiss; P Antal-Szalmás; G Szegedi; P Gergely
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 2.  Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome.

Authors:  Stefano Turolo; Alberto Edefonti; Alessandra Mazzocchi; Marie Louise Syren; William Morello; Carlo Agostoni; Giovanni Montini
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.